- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Adenomyosis.
Displaying page 1 of 1.
EudraCT Number: 2017-005022-38 | Sponsor Protocol Number: T366/2017 | Start Date*: 2018-06-13 | ||||||||||||||||
Sponsor Name:Turku University Hospital | ||||||||||||||||||
Full Title: Oxytocin in mr guided focused ultrasound treatment (MRI-HIFU) | ||||||||||||||||||
Medical condition: women with uterine fibroids or adenomyosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: FI (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004042-14 | Sponsor Protocol Number: 16-OBE2109-015 | Start Date*: 2018-04-23 | |||||||||||
Sponsor Name:ObsEva SA | |||||||||||||
Full Title: An exploratory single centre, open label, pilot study investigating the efficacy and safety of OBE2109 200 mg daily for 12 weeks followed by 100 mg daily for 12 weeks in uterine adenomyosis. | |||||||||||||
Medical condition: Uterine adenomyosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000915-26 | Sponsor Protocol Number: 000295 | Start Date*: 2019-05-10 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, proof-of-mechanism phase 2 trial investigating the effect of quinagolide extended-release vaginal ring on reduction of lesions assessed by high-resol... | |||||||||||||
Medical condition: Deep infiltrating endometriosis, endometrioma and/or adenomyosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003645-16 | Sponsor Protocol Number: 2019_0012 | Start Date*: 2020-02-25 |
Sponsor Name:Hopital Foch | ||
Full Title: Benefit of the GnRH agonist before frozen embryo transfer in patients with endometriosis and / or adenomyosis: randomized prospective study | ||
Medical condition: Frozen embryo transfer in patients with endometriosis and/or adenomyosis | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005005-28 | Sponsor Protocol Number: ADENOFERT | Start Date*: 2022-11-08 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA | |||||||||||||
Full Title: Assisted reproductive technology (ART) and pregnancy outcomes in women with adenomyosis (internal endometriosis) according to stimulation protocol in relation to immunological and endometrial featu... | |||||||||||||
Medical condition: Women with transvaginal ultrasound (TV-US)-based diagnosis of adenomyosis and women without adenomyosis but with similar baseline reproductive risks | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001830-32 | Sponsor Protocol Number: RC31/17/0448 | Start Date*: 2019-12-18 |
Sponsor Name:University Hospital Toulouse | ||
Full Title: Phase III Trial to assess impact of ultra-long versus long down-regulation protocol on IVF/ICSI outcomes in infertile women presenting with adenomyosis. | ||
Medical condition: Infertilty in women with adenomyosis. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-003810-13 | Sponsor Protocol Number: 000289 | Start Date*: 2018-05-21 | |||||||||||||||||||||||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||||||||||||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, parallel-group, dose-range trial to investigate the efficacy and safety of FE 999302 as add-on treatment to follitropin delta (REKOVELLE) in women un... | |||||||||||||||||||||||||||||||||
Medical condition: Women diagnosed with tubal infertility or unexplained infertility or endometriosis stage I/II or having partners diagnosed with male factor infertility, eligible for IVF and/or ICSI. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||||||||||||
Trial protocol: CZ (Completed) DK (Completed) BE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002783-40 | Sponsor Protocol Number: 000304 | Start Date*: 2019-07-04 | |||||||||||||||||||||||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||||||||||||||||||||||
Full Title: A randomised, controlled, open label, parallel group, multicentre trial comparing the efficacy and safety of individualised FE 999049 (follitropin delta) dosing, using a long GnRH agonist protocol ... | |||||||||||||||||||||||||||||||||
Medical condition: Infertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||||||||||||
Trial protocol: AT (Completed) DK (Completed) NO (Completed) NL (Completed) IT (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004326-34 | Sponsor Protocol Number: MK8342B-060 | Start Date*: 2016-02-12 | ||||||||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||||||||||||||||||
Full Title: A Phase 3 Randomized, Double-blind, Placebo-Controlled Trial to Study the Efficacy and Safety of MK-8342B (ENG-E2 vaginal ring) in Women with Moderate to Severe Primary Dysmenorrhea. | ||||||||||||||||||
Medical condition: Moderate to severe primary dysmenorrhea | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | |||||||||||||||||
Trial protocol: SE (Completed) PL (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004325-14 | Sponsor Protocol Number: MK8342B-059 | Start Date*: 2016-04-15 | ||||||||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc. | ||||||||||||||||||
Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Study the Efficacy and Safety of MK-8342B (ENG-E2 Vaginal Ring) in Women with Moderate to Severe Primary Dysmenorrhea (with Optional ... | ||||||||||||||||||
Medical condition: Treatment of primary dysmenorrhea | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | |||||||||||||||||
Trial protocol: DE (Completed) FI (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.